UROLOGY MAIN SITE GEN. ADULT UROLOGY UROLOGIC ONCOLOGY MALE UROLOGY TRANSPLANT PROGRAM
PELVIC MEDICINE, INCONTINENCE & RECONST. SURGERY PEDIATRIC UROLOGY MIN. INVASIVE SURGERY
About Us
Our History
Faculty Information
Conditions
Innovations & Technology
Research & Clinical
Trials
For Patients
Academic Information
News & Events
Useful Links
Department Directory
Facilities & Directions
How You Can Help
Contact Us
Department of
Urology Intranet

Clinical Trial Details

Trial Information
 
Trial:  Kidney Cancer - Metastatic RCC – PREVIOUSLY TREATED
   
 
Co-Investigator(s):  Arie Belldegrun, MD;
   
This trial is currently accepting new patient applications.  (Apply)


Objective
 

A Phase II Study of Recombinant Human Lactoferrin in Patients with Advanced RCC who have Failed At Least one Regimen of Systemic Treatment.

 

Recombinant Lactoferrin is structurally and functionally equivalent to native lactoferrin that is found in human milk.  Like the native protein, rhLF displays anti-neoplastic and immunomodulatory properties.  Recent investigations have shown a wide array of functions of lactoferrin that are related to host primary defense mechanisms.  Lactoferrin has been found to inhibit metastasis and carcinogenesis in many in vivo models.

 

Principal investigator: Fairooz Kabbinavar - Hematology-Oncolory


Patient Eligibility
 

Inclusion Criteria:

·        Advanced RCC with clear cell histology: nephrectomy not required.

·        Failed at least one regimen of systemic therapy for RCC

·        Measurable disease according to RECIST

·        Karnofsky PS >70

 

Exclusion Criteria:

  •  Papillary or chromophobe pathology, collecting duct, mixed histologies,  transitional cell tumors, tumors that contain any sarcomatoid features.
  • Brain Metastases
  •  Ischemic Heart Disease, CHF
  • Autoimmune diseases
  • Steroid Therapy
  • HIV positive


For More Information
  For additional information on inclusion and exclusion criteria and whether or not you may be a candidate to participate in a trial, call Nazy Zomorodian, Director for the Clinical Trials Office at (310) 794-7704.